We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

32 hedge funds and large institutions have $7.26M invested in Gyre Therapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $25K | Put options by funds: $13K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 35 → 32 (-3)

48% less capital invested

Capital invested by funds: $13.9M → $7.26M (-$6.64M)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

82% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 11

Holders
32
Holders Change
-3
Holders Change %
-8.57%
% of All Funds
0.85%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
2
Reduced
11
Closed
4
Calls
$25K
Puts
$13K
Net Calls
+$12K
Net Calls Change
-$34K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$52.8K
2
Morgan Stanley
Morgan Stanley
New York
+$723
3
Vanguard Group
Vanguard Group
Pennsylvania
+$241

Top Sellers

1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$68.2K
2
DCM
DG Capital Management
New York
-$63.4K
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$46K
4
Renaissance Technologies
Renaissance Technologies
New York
-$21.7K
5
SIM
Spark Investment Management
New York
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
EWM
1
Essex Woodlands Management
Texas
$2.02M – – –
BI
2
BVF Inc
California
$1.63M – – –
NMC
3
NEA Management Company
Maryland
$1.1M – – –
UBS Group
4
UBS Group
Switzerland
$594K -$9.16K -38 -1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$405K +$241 +1 +0%
BIT
6
BlackRock Institutional Trust
California
$272K -$6.75K -28 -2%
DCM
7
DG Capital Management
New York
$261K -$63.4K -263 -16%
CCM
8
Colorado Capital Management
Colorado
$131K – – –
ACA
9
Avoro Capital Advisors
New York
$120K – – –
DCM
10
DAFNA Capital Management
California
$119K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$112K -$21.7K -90 -13%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$112K -$1.21K -5 -0.8%
Goldman Sachs
13
Goldman Sachs
New York
$83K -$7.96K -33 -7%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$67K -$68.2K -283 -44%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$41K +$52.8K +219 New
NMIMC
16
Northwestern Mutual Investment Management Company
Wisconsin
$39K – – –
SIM
17
Spark Investment Management
New York
$32K -$14K -58 -25%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$31K – – –
AIA
19
Arbor Investment Advisors
North Carolina
$25K – – –
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$23K – – –
BFA
21
BlackRock Fund Advisors
California
$17K -$964 -4 -4%
Morgan Stanley
22
Morgan Stanley
New York
$17K +$723 +3 +3%
BJ
23
BlackRock Japan
Japan
$4K -$241 -1 -5%
Deutsche Bank
24
Deutsche Bank
Germany
$2K -$4.1K -17 -55%
BIM
25
BlackRock Investment Management
Delaware
$2K – – –
1
2

GYRE Hedge Fund Activity: Q1 2016 in Review

32 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2016, worth a combined $7.26M — down 48% from $13.9M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GYRE and 1 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 2 added.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $52.8K. The largest seller was D.E. Shaw & Co, cutting an estimated $68.2K.

  • 32 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2016, down from 35 in Q4 2015.
  • Funds reported $7.26M of Gyre Therapeutics stock for Q1 2016, down 48% quarter-over-quarter.
  • 1 fund opened new Gyre Therapeutics positions in Q1 2016 and 4 closed out, a net change of -3 holders.
  • The largest Gyre Therapeutics buyer in Q1 2016 was T. Rowe Price Associates, an estimated $52.8K added.
  • The largest Gyre Therapeutics seller in Q1 2016 was D.E. Shaw & Co, an estimated $68.2K sold.

Based on aggregated 13F filings for Q1 2016.